(XRX) Xerox - Overview
Stock: Printers, Copiers, Scanners, Software, Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.77% |
| Yield on Cost 5y | 1.20% |
| Yield CAGR 5y | -33.13% |
| Payout Consistency | 82.1% |
| Payout Ratio | 94.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 76.8% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.57 |
| Alpha | -98.66 |
| Character TTM | |
|---|---|
| Beta | 1.730 |
| Beta Downside | 1.645 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.11% |
| CAGR/Max DD | -0.53 |
Description: XRX Xerox December 25, 2025
Xerox Holdings Corp. (NASDAQ:XRX) operates as a global workplace-technology firm, blending hardware, software, and services across North America, Latin America, Europe, the Middle East, Africa, India, and other markets. Its operations are split between the Print & Other segment-covering document systems, multifunction printers, production presses, and the ConnectKey software suite-and Xerox Financial Services (XFS), which provides equipment financing and leasing solutions.
In FY 2024 Xerox reported revenue of roughly $7.2 billion, with the Print & Other segment contributing about 78% and an operating margin that improved to 7.5% versus 5.9% the prior year, driven by higher Managed Print Services (MPS) adoption. The company’s growth is closely tied to macro trends such as corporate digital-transformation spending, remote-work-induced demand for secure document workflow solutions, and the broader shift toward subscription-based services in the technology-hardware sector. Additionally, Xerox’s exposure to financing through XFS adds a low-correlation cash-flow stream that can cushion cyclical swings in equipment sales.
If you want a data-rich, model-backed assessment of XRX’s valuation and risk profile, ValueRay’s analyst notes provide a concise next step for deeper research.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -1.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.51 > 1.0 |
| NWC/Revenue: 5.40% < 20% (prev 5.08%; Δ 0.32% < -1%) |
| CFO/TA 0.03 > 3% & CFO 267.0m > Net Income -1.03b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.0m) vs 12m ago 2.92% < -2% |
| Gross Margin: 66.29% > 18% (prev 0.32%; Δ 6598 % > 0.5%) |
| Asset Turnover: 77.23% > 50% (prev 74.37%; Δ 2.86% > 0%) |
| Interest Coverage Ratio: -1.97 > 6 (EBITDA TTM -157.0m / Interest Expense TTM 248.0m) |
Altman Z'' 0.62
| A: 0.04 (Total Current Assets 3.61b - Total Current Liabilities 3.23b) / Total Assets 9.82b |
| B: 0.25 (Retained Earnings 2.44b / Total Assets 9.82b) |
| C: -0.05 (EBIT TTM -488.0m / Avg Total Assets 9.09b) |
| D: -0.08 (Book Value of Equity -739.0m / Total Liabilities 9.15b) |
| Altman-Z'' Score: 0.62 = B |
Beneish M -3.49
| DSRI: 1.02 (Receivables 1.70b/1.47b, Revenue 7.02b/6.22b) |
| GMI: 0.48 (GM 66.29% / 31.51%) |
| AQI: 1.06 (AQ_t 0.60 / AQ_t-1 0.57) |
| SGI: 1.13 (Revenue 7.02b / 6.22b) |
| TATA: -0.13 (NI -1.03b - CFO 267.0m) / TA 9.82b) |
| Beneish M-Score: -3.49 (Cap -4..+1) = AA |
What is the price of XRX shares?
Over the past week, the price has changed by -1.35%, over one month by -10.98%, over three months by -31.29% and over the past year by -72.30%.
Is XRX a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the XRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.3 | 48.4% |
| Analysts Target Price | 3.3 | 48.4% |
| ValueRay Target Price | 1.3 | -39.3% |
XRX Fundamental Data Overview January 31, 2026
P/S = 0.038
P/B = 0.5869
P/EG = 0.1984
Revenue TTM = 7.02b USD
EBIT TTM = -488.0m USD
EBITDA TTM = -157.0m USD
Long Term Debt = 4.05b USD (from longTermDebt, two quarters ago)
Short Term Debt = 231.0m USD (from shortTermDebt, last quarter)
Debt = 4.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.73b USD (from netDebt column, last quarter)
Enterprise Value = 4.00b USD (267.0m + Debt 4.25b - CCE 512.0m)
Interest Coverage Ratio = -1.97 (Ebit TTM -488.0m / Interest Expense TTM 248.0m)
EV/FCF = 13.25x (Enterprise Value 4.00b / FCF TTM 302.0m)
FCF Yield = 7.55% (FCF TTM 302.0m / Enterprise Value 4.00b)
FCF Margin = 4.30% (FCF TTM 302.0m / Revenue TTM 7.02b)
Net Margin = -14.65% (Net Income TTM -1.03b / Revenue TTM 7.02b)
Gross Margin = 66.29% ((Revenue TTM 7.02b - Cost of Revenue TTM 2.37b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 59.82%)
Tobins Q-Ratio = 0.41 (Enterprise Value 4.00b / Total Assets 9.82b)
Interest Expense / Debt = 1.88% (Interest Expense 80.0m / Debt 4.25b)
Taxrate = 21.0% (US default 21%)
NOPAT = -385.5m (EBIT -488.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.12 (Total Current Assets 3.61b / Total Current Liabilities 3.23b)
Debt / Equity = 6.45 (Debt 4.25b / totalStockholderEquity, last quarter 658.0m)
Debt / EBITDA = -23.79 (negative EBITDA) (Net Debt 3.73b / EBITDA -157.0m)
Debt / FCF = 12.37 (Net Debt 3.73b / FCF TTM 302.0m)
Total Stockholder Equity = 960.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.32% (Net Income -1.03b / Total Assets 9.82b)
RoE = -107.2% (Net Income TTM -1.03b / Total Stockholder Equity 960.0m)
RoCE = -9.74% (EBIT -488.0m / Capital Employed (Equity 960.0m + L.T.Debt 4.05b))
RoIC = -8.15% (negative operating profit) (NOPAT -385.5m / Invested Capital 4.73b)
WACC = 2.13% (E(267.0m)/V(4.51b) * Re(12.29%) + D(4.25b)/V(4.51b) * Rd(1.88%) * (1-Tc(0.21)))
Discount Rate = 12.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.00%
[DCF Debug] Terminal Value 86.71% ; FCFF base≈368.0m ; Y1≈382.2m ; Y5≈436.6m
Fair Price DCF = 72.11 (EV 12.97b - Net Debt 3.73b = Equity 9.23b / Shares 128.0m; r=5.90% [WACC]; 5y FCF grow 4.06% → 2.90% )
EPS Correlation: -38.76 | EPS CAGR: 0.96% | SUE: -1.89 | # QB: 0
Revenue Correlation: -5.73 | Revenue CAGR: 5.35% | SUE: -0.52 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.27 | Chg30d=-0.228 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=0.77 | Chg30d=-0.294 | Revisions Net=+0 | Growth EPS=+228.7% | Growth Revenue=+9.8%
EPS next Year (2027-12-31): EPS=1.28 | Chg30d=-0.061 | Revisions Net=-1 | Growth EPS=+66.0% | Growth Revenue=-0.5%